Latham & Watkins advised Crinetics, and Cooley advised the underwriters on the offering. Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced the pricing of an upsized underwritten public...
Crinetics Pharmaceuticals’ $350 Million Public Offering of Common Stock
Crinetics’ Launch of Radionetics Oncology
Wilson Sonsini Goodrich & Rosati advised Crinetics on the deal. Crinetics Pharmaceuticals, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel...